Lanlan Pang
YOU?
Author Swipe
View article: Minimally invasive management of deep incisional infection following posterior spinal surgery: a case report
Minimally invasive management of deep incisional infection following posterior spinal surgery: a case report Open
Background In recent years, innovations in spinal surgical techniques have significantly improved clinical outcomes and quality of life for patients with spinal diseases. However, the risk of deep surgical site infection (SSI) following po…
View article: Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis Open
Background: Traditional chemotherapy provides restricted benefits for advanced EGFR -mutant non–small cell lung cancer (NSCLC) after failure of EGFR-tyrosine kinase inhibitors (EGFR-TKIs), necessitating the combined treatment. However, it …
View article: Immunotherapy efficacy between exon 19 deletion and exon 21 L858R mutation in advanced EGFR mutant non-small-cell lung cancer: a direct and indirect meta-analysis
Immunotherapy efficacy between exon 19 deletion and exon 21 L858R mutation in advanced EGFR mutant non-small-cell lung cancer: a direct and indirect meta-analysis Open
For advanced EGFR mutant NSCLC patients, 21 L858R had superior IO efficacy compared with 19 Del.
View article: Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial
Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial Open
The traditional Chinese medicine compound preparation known as Jinbei Oral Liquid (JBOL) consists of 12 herbs, including Astragalus membranaceus (Fisch.) Bge, Codonopsis pilosula (Franch.) Nannf, et al. Having been used for over 30 years i…
View article: Long-term outcome of the vaginoscopic approach for infantile vaginal yolk sac tumors: A case report
Long-term outcome of the vaginoscopic approach for infantile vaginal yolk sac tumors: A case report Open
The vaginoscopic approach provides a significant alternative for treating vaginal YSTs, especially in cases where AFP levels rise post-chemotherapy. This method emphasizes fertility preservation and minimizes the impact on reproductive hea…
View article: Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation
Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation Open
The present study comprehensively elucidates the molecular features of EGFR p.L861Q mutation and underscores the optimal therapeutic choice of first-line EGFR-TKI based on brain metastatic status.
View article: Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy
Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy Open
Our study extended our understanding of the AHNAK family in promoting GI and selecting treatment responders of ESCC.
View article: Supplementary Table 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 2. Baseline characteristics of treatment-naive patients diagnosed with NSCLC who harbored EGFR G719X mutation in SYSUCC cohort (n=48)
View article: Supplementary Table 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 3. List of genes included in the Mygene Diagnostics NGS panel. (Ion AmpliSeq Colon and Lung Cancer Research Panel v2 and Ion AmpliSeq RNA Fusion gene list)
View article: Supplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 5. Baseline characteristics of TKI-naive EGFR p.G719X mutant patients diagnosed with NSCLC who received Afatinib or the third-generation EGFR-TKIs(N=68)
View article: Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 1. Study design.
View article: Supplementary Table 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 1. Representativeness of Study Participants
View article: Supplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 5. Baseline characteristics of TKI-naive EGFR p.G719X mutant patients diagnosed with NSCLC who received Afatinib or the third-generation EGFR-TKIs(N=68)
View article: Supplementary Table 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 4. List of genes included in the SYSUCC Personalized Diagnostics Panel (Tumor tissue and blood sample control)
View article: Data from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Data from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Purpose:The current National Comprehensive Cancer Network (NCCN) guidelines recommend afatinib or osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC harboring EGFR p.G719X mutation. However, in the …
View article: Supplementary Figure 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 4. Drug sensitivity of different EGFR-TKIs in Ba/F3 cells expressing indicated EGFR p.G719S or EGFR p.E709K/G719S. (Data obtained from a public dataset of one published article, Reference: Nature. 2021 Sep; 597(7878):7…
View article: Supplementary Figure 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 5 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 5. Structural modeling of EGFR p.G719A/E709K in a complex with afatinib.
View article: Supplementary Figure 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 2. Impact of EGFR p.E709X mutation in patients harboring EGFR p.G719X mutant patients and genomic features of EGFR p.G719X mutant patients with NSCLC in the validation cohort.
View article: Supplementary Figure 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 3. Genomic characteristics was found between patients receiving afatinib or the third-generation EGFR-TKIs.
View article: Supplementary Table 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 1. Representativeness of Study Participants
View article: Supplementary Table 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 3. List of genes included in the Mygene Diagnostics NGS panel. (Ion AmpliSeq Colon and Lung Cancer Research Panel v2 and Ion AmpliSeq RNA Fusion gene list)
View article: Supplementary Table 6 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 6 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 6. Literature review: response to EGFR-TKIs (Afatinib or Osimertinib) in EGFR p.G719X-mutant patients with advanced NSCLC (Sample size≥10)
View article: Supplementary Figure 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 4. Drug sensitivity of different EGFR-TKIs in Ba/F3 cells expressing indicated EGFR p.G719S or EGFR p.E709K/G719S. (Data obtained from a public dataset of one published article, Reference: Nature. 2021 Sep; 597(7878):7…
View article: Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 1. Study design.
View article: Supplementary Figure 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Figure 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Figure 3. Genomic characteristics was found between patients receiving afatinib or the third-generation EGFR-TKIs.
View article: Supplementary Table 6 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Supplementary Table 6 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Supplementary Table 6. Literature review: response to EGFR-TKIs (Afatinib or Osimertinib) in EGFR p.G719X-mutant patients with advanced NSCLC (Sample size≥10)
View article: Data from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Data from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC Open
Purpose:The current National Comprehensive Cancer Network (NCCN) guidelines recommend afatinib or osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC harboring EGFR p.G719X mutation. However, in the …